Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD
- PMID: 6771090
- DOI: 10.1016/0010-7824(80)90003-7
Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD
Abstract
Plasma concentrations of levonorgestrel, progesterone, estradiol, FSH and LH were measured in seven volunteers who had a levonorgestrel-releasing IUD inserted postmenstrually. Blood samples were collected twice weekly during a mean of 93 days immediately postmenstrually and during a mean of 41 days over the twelfth to fifteenth month of treatment. Patterns of bleeding were studied during the first year of treatment. The IUDs used were designed to release 25 micrograms/day of levonorgestrel. The mean +/- SD plasma concentration of levonorgestrel for all subjects during the first three months was 260 +/- 68 pg/ml, and 129 +/- 28 pg/ml after one year of treatment. During the initial period of blood sampling only two of the subjects ovulated, while only two did not ovulate after one year of treatment. Intermenstrual spotting occurred during the first sixty days of treatment. Three subjects developed amenorrhea at the end of the first year. All the subjects continued the use of the IUD and no pregnancies occurred.
PIP: Steroid profiles of women wearing levonorgestrel-containing IUDs during the first 3 months of treatment were compared with those from the same subject after 1 year of treatment. Bleeding patterns were also studied in the 7 volunteers in this study. Plasma concentrations of levonorgestrel, progesterone, estradiol, follicle stimulating hormone, and luteinizing hormone were assayed in blood samples collected 2 times/week during a mean of 93 days immediately postmenstrually and during a mean of 41 days over the 12th-15th month of treatment. The medicated IUDs were designed to release 25 mcg of steroid per day. Steroid profiles showed that during the initial period of blood sampling only 2 subjects ovulated, but by 1 year only 2 of 7 had not ovulated. Levonorgestrel concentrations (mean) were 260+ or -68 pg/ml during the first 3 months and 129+ or -28 pg/ml at the end of 1 year of treatment. After the 1-year trial, all subjects continued using the medicated IUD and no pregnancies have occurred. Bleeding side effects were mostly spotting and intermenstual bleeding during the first 60 days of treatment; however, 3 subjects had developed amenorrhea by the end of the first year of treatment.
Similar articles
-
Patterns of ovulation and bleeding with a low levonorgestrel-releasing intrauterine device.Contraception. 1980 Feb;21(2):155-64. doi: 10.1016/0010-7824(80)90127-4. Contraception. 1980. PMID: 6768490
-
Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.Contraception. 1995 Jun;51(6):359-65. doi: 10.1016/0010-7824(95)00102-g. Contraception. 1995. PMID: 7554977 Clinical Trial.
-
Sustained intrauterine release of levonorgestrel over five years.Fertil Steril. 1986 Jun;45(6):805-7. doi: 10.1016/s0015-0282(16)49397-0. Fertil Steril. 1986. PMID: 3086130 Clinical Trial.
-
Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.Contraception. 1995 Nov;52(5):269-76. doi: 10.1016/0010-7824(95)00210-2. Contraception. 1995. PMID: 8585882 Review.
-
An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.Contraception. 1991 Dec;44(6):573-88. doi: 10.1016/0010-7824(91)90078-t. Contraception. 1991. PMID: 1773615 Review.
Cited by
-
An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.Drug Deliv Transl Res. 2017 Dec;7(6):840-858. doi: 10.1007/s13346-017-0389-0. Drug Deliv Transl Res. 2017. PMID: 28600625 Free PMC article.
-
Effect of domestically-made levonorgestrel-releasing intrauterine device on the endocrine system and menstruation in monkeys.J Tongji Med Univ. 1996;16(2):117-20. doi: 10.1007/BF02887971. J Tongji Med Univ. 1996. PMID: 9275705
-
Evaluating the impact of three progestin-based hormonal contraceptive methods on immunologic changes in the female genital tract and systemically (CHIME Study): a prospective cohort study protocol.BMC Womens Health. 2022 Nov 18;22(1):456. doi: 10.1186/s12905-022-02053-w. BMC Womens Health. 2022. PMID: 36401326 Free PMC article.
-
The Effects of Sex Differences and Hormonal Contraception on Outcomes after Collegiate Sports-Related Concussion.J Neurotrauma. 2018 Jun 1;35(11):1242-1247. doi: 10.1089/neu.2017.5453. Epub 2018 Mar 27. J Neurotrauma. 2018. PMID: 29336208 Free PMC article.
-
A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.Drug Saf. 1996 Dec;15(6):430-40. doi: 10.2165/00002018-199615060-00006. Drug Saf. 1996. PMID: 8968696 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources